GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.
OpenAI is framing GPT-Rosalind as a tool to compress the timeline from scientific idea to clinical evidence. The company ...
Getting a drug from initial target discovery to U.S. regulatory approval takes between 10 and 15 years on average. Most of ...
Credit: VentureBeat made with OpenAI GPT-Image-1.5 The journey from a laboratory hypothesis to a pharmacy shelf is one of the ...
Rosalind, a specialised AI model designed for life sciences. Built to assist researchers with complex biological problems, ...
Nvidia's Nemotron-Cascade 2 is a 30B MoE model that activates only 3B parameters at inference time, yet achieved gold medal-level performance at the 2025 IMO, IOI, and ICPC World Finals. Nvidia has ...
Artificial intelligence-native security platform startup depthfirst Inc. announced today that it has raised $80 million in ...
GPT-Rosalind, a specialized AI model developed by OpenAI, focuses on life sciences and biomedical research. The launch ...
Materials research suffers from trial-and-error synthesis and fabrication, while the resulting numerical datasets fail to ...
The next important milestone for AI research is to automate model development. Every advance in reasoning, language, and perception is, in some sense, a step toward that goal. However, the path to ...
Foundation models are commoditizing. The real competitive advantage in enterprise AI has quietly moved to the operating layer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results